



January 22, 2021

Web Announcement 2414

New 2021 Diagnosis and Procedure Codes Related to COVID-19

Effective with dates of service on or after January 1, 2021, six new 2021 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Novel Coronavirus (COVID-19) diagnosis codes and 21 new International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) COVID-19 procedure codes have been added to the Medicaid Management Information System (MMIS) for billing.

The six ICD-10-CM diagnosis codes implemented by the Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS) are:

Diagnosis Code	Code Description
J12.82	Pneumonia due to coronavirus disease 2019
M35.81	Multisystem inflammatory syndrome
M35.89	Other specified systemic involvement of connective tissue
Z11.52	Encounter for screening for COVID-19
Z20.822	Contact with and (suspected) exposure to COVID-19
Z86.16	Personal history of COVID-19

The 21 ICD-10-PCS procedure codes implemented by the Centers for Medicare & Medicaid Services (CMS) are:

Procedure Code	Code Description
XW013H6	Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013K6	Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW012S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW012T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Procedure Code	Code Description
XW033G6	Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H6	Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H6	Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6